GlaxoSmithKline plc's RTS,S vaccine won accolades last week for its Phase III success against malaria, but perhaps less recognized was the product's signal of progress in the adjuvant development field. Read More
ChemoCentryx Inc. and Cempra Holdings LLC just filed S-1s within a week of each other, joining the limited number of biotechs looking to test the initial public offering (IPO) waters. (See BioWorld Today, Oct. 14, 2011, and Oct. 18, 2011.) Read More
